News & Events
Tuesday February 14, 2017
INGREZZATM New Drug Application PDUFA Action Date of April 11, 2017 Acquired U.S. Rights to Opicapone for Parkinson's Disease Elagolix New Drug Application Submission for Endometriosis Expected in Third Quarter of 2017 Two Phase III Studies of Elagolix in Uterine Fibroids Underway, Top-Line Data End of Year Phase II Study of Valbenazine in Pediatric Tourette Syndrome Expected to Readout in Second Quarter 2017 Phase II Trial for Essential Tremor Drug Candidate NBI-640756 Planned for 2017 SAN DIEGO, Feb. 14, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter and full year 2016, and highlighted recent progress on it...
Thursday February 09, 2017
Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease ONGENTYS® (opicapone) Approved in Europe in June 2016 Neurocrine to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO and PORTO, Portugal, Feb. 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and BIAL today announced that they have entered into an exclusive licensing agreement for the development and commercialization of opicapone in North America. ONGENTYS® (opicapone) is a once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor (COMT inhibitor) that was approved in June 2016 by the European Commission as...
Tuesday February 07, 2017
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
Conference Call and Webcast Scheduled for Tuesday, February 14, 2017 SAN DIEGO, Feb. 7, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter 2016 results after the Nasdaq market closes on Tuesday, February 14, 2017. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, February 14, 2017 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 888-632-3382 (US) or 785-424-1677 (International) using the conference ID NBIX. The call can also be accessed via the webcast thr...
Tuesday January 17, 2017
Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed a significant improvement in overall symptoms of Tourette syndrome as evidenced by the Clinical Global Impression of Change (p=0.015), the pre-specified primary endpoint, the change-from-baseline in th...
Friday January 06, 2017
Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer
SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer. "Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences. "DA's breadth of experience across all aspects of drug development and commercialization will be of critical importance as we enter this period of rapid growth. He wil...
Tuesday February 14, 2017